{"id":3018,"date":"2026-11-17T17:58:01","date_gmt":"2026-11-17T17:58:01","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-11-17T17:58:30","modified_gmt":"2026-11-17T17:58:30","slug":"admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/","title":{"rendered":"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><em>Portfolio progress highlights the value of commercialization support as Canadian life sciences investment falls 31 per cent in Q3 2026<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Vancouver (BC), Toronto (ON), and Montreal (QC), November 17, 2026<\/strong> \u2014 adMare BioInnovations today announced significant progress across its portfolio of Canadian life sciences companies, which are attracting new investors, entering the clinic and reaching key research milestones despite a challenging investment climate.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">New data from the Canadian Venture Capital &amp; Private Equity Association (CVCA) shows the scale of the challenge. Life sciences venture investment in Canada fell 31 per cent to $534 million across 72 deals in the first three quarters of 2026. That is the lowest year-to-date total since 2021 and half the five-year average of $1.07 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Globally, life sciences venture capital is concentrating in larger, more de-risked deals, creating a growing funding gap for early-stage companies. CVCA\u2019s data underscores this point. &nbsp;In the third quarter, one single deal captured 86 per cent of the $239 million investment, leaving just $34 million across the remaining 16 deals. This widening gap puts promising Canadian companies at risk, threatening their ability to develop promising treatments, grow and keep jobs in Canada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Canada has strong science and entrepreneurial ambition to develop new treatments and compete on a global scale. What&#8217;s missing is the middle: turning those start-ups into companies investors can back,\u201d said Matthew Carlyle, President and CEO of adMare BioInnovations. \u201cOur portfolio shows what\u2019s possible when promising science gets the capital, expertise and support to reach the milestones investors look for.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Despite the declining investment landscape, adMare portfolio companies continue to advance, benefiting from the organization\u2019s proven life sciences company creation model and partnership with the Government of Canada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Recent milestones span the research translation journey and help bring new treatments closer to patients:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Scientific validation and company creation:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ocythera &#8211; Progress toward new treatments for bone and joint diseases:<\/strong> Building ona multi-year research collaboration with Queen\u2019s University, adMare launched Ocythera in January 2026 and co-invested in its seed financing alongside Investissement Qu\u00e9bec&#8217;s Fonds Impulsion. Ocythera is developing drugs that block CYP26B1, an enzyme involved in bone and cartilage development. \u00a0Since launch it has met every milestone in its development plan, with drug candidates showing \u00a0favourable preclinical results for the potential of treating several bone diseases, including multiple osteochondromas, fibrodysplasia ossificans progressiva and osteoarthritis.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Crossing the valley of death:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Specific Biologics \u2013 Securing a Series A investment to bring a potential ALS treatment to clinical trials:<\/strong> \u00a0Building on its early investment and several years of commercial research support, adMare participated in Specific Biologics\u2019 US$35 million Series A financing to advance the company&#8217;s lead ALS program into the clinic. New investors Hatteras Venture Partners, Genesys Capital, BDC, Seido and Deepworks joined original investors Lumira Ventures and adMare. The financing also marked the first investment by BDC&#8217;s new Life Sciences Fund.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In the clinic:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epitopea: Testing a potential ovarian cancer vaccine<\/strong>: Epitopea has treated the first patient in its OVACT Phase 1\/1b clinical trial. \u00a0The study is testing the potential benefits of its off-the-shelf therapeutic mRNA cancer vaccine candidate, for advanced ovarian cancer.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Kainova Therapeutics<\/strong> &#8211; <strong>advancing cancer treatments:<\/strong> adMare has been a consistent investor in Kainova since its expansion to Canada in 2022. Recent financing from Canadian and European investors will support a Phase 1\/2 clinical trial, to test the company&#8217;s anti-CCR8 antibody against solid tumor cancers.<\/li>\n\n\n\n<li><strong>Find Therapeutics \u2013 preparing for Phase 2 clinical trial<\/strong>: Investments from CTI Life Sciences, Investissement Qu\u00e9bec and adMare will allow the company to complete safety and manufacturing work ahead of its next Phase 2 trial. Find is focused on developing therapies aimed at treating demyelinating diseases and inflammatory autoimmune conditions, such as acute optic neuritis and chronic optic neuropathy.<\/li>\n\n\n\n<li><strong>Thryv Therapeutics \u00a0\u2013 advancing potential treatments for serious heart conditions:<\/strong> adMare re-invested as part of Thryv\u2019s US$30 million+ Series B financing with new investor InClin and existing investors, Amplitude Ventures, Fonds de solidarit\u00e9 FTQ, Lumira Ventures, Investissement Qu\u00e9bec, CTI Life Sciences and Alexandria Venture Investments. This financing will support ongoing Phase 2\/3 clinical studies in long QT syndrome, which causes dangerous heart rhythms, and a Phase 2a trial to treat heart failure with reduced ejection fraction.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bridging the gap between discovery and investability<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Recent federal measures strengthen both ends of the life sciences pipeline: new research chairs on the discovery side, and new tax incentives and venture capital, including BDC&#8217;s Life Sciences Fund, on the investment side.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As the federal government considers its response to the Pharmaceutical and Life Sciences Task Force and shapes the next phase of Canada&#8217;s life sciences strategy, strengthening the bridge between research and private investment will be essential to building globally competitive Canadian companies and keeping more of the value of Canadian science in Canada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">-30-<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About adMare BioInnovations<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As Canada\u2019s life sciences company creation engine, adMare BioInnovations develops and helps scale a pipeline of highly investable, globally competitive life sciences companies. Through early-stage capital, scientific and drug development expertise, turnkey lab and office facilities, and focused talent and leadership development programs, adMare fills critical gaps to de-risk and accelerate innovation, create value, and anchor growth\u2014helping to improve patient lives and achieve the vision of a national life sciences industry that leverages Canada\u2019s scientific research excellence. The organization has helped build 54 Canadian life sciences companies that have raised $2.5B in risk capital, have a collective value of $5.8B and created more than 1000 jobs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Portfolio progress highlights the value of commercialization support as Canadian life sciences investment falls 31 per cent in Q3 2026 Vancouver (BC), Toronto (ON), and Montreal (QC), November 17, 2026 [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":3023,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"company":[127,78,83,79,82,80,18],"class_list":["post-3018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-admare-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low | adMare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/admarebio.com\/en\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low | adMare\" \/>\n<meta property=\"og:description\" content=\"Portfolio progress highlights the value of commercialization support as Canadian life sciences investment falls 31 per cent in Q3 2026 Vancouver (BC), Toronto (ON), and Montreal (QC), November 17, 2026 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T17:58:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-17T17:58:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/Annonce-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Alexis Bouffioux\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis Bouffioux\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/\"},\"author\":{\"name\":\"Alexis Bouffioux\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\"},\"headline\":\"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low\",\"datePublished\":\"2026-11-17T17:58:01+00:00\",\"dateModified\":\"2026-11-17T17:58:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/\"},\"wordCount\":908,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Annonce-1.png\",\"articleSection\":[\"adMare News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/\",\"name\":\"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Annonce-1.png\",\"datePublished\":\"2026-11-17T17:58:01+00:00\",\"dateModified\":\"2026-11-17T17:58:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Annonce-1.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Annonce-1.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\",\"name\":\"Alexis Bouffioux\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low | adMare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/","og_locale":"en_US","og_type":"article","og_title":"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low | adMare","og_description":"Portfolio progress highlights the value of commercialization support as Canadian life sciences investment falls 31 per cent in Q3 2026 Vancouver (BC), Toronto (ON), and Montreal (QC), November 17, 2026 [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/","og_site_name":"adMare","article_published_time":"2026-11-17T17:58:01+00:00","article_modified_time":"2026-11-17T17:58:30+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/Annonce-1.png","type":"image\/png"}],"author":"Alexis Bouffioux","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Alexis Bouffioux","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/"},"author":{"name":"Alexis Bouffioux","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add"},"headline":"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low","datePublished":"2026-11-17T17:58:01+00:00","dateModified":"2026-11-17T17:58:30+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/"},"wordCount":908,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/Annonce-1.png","articleSection":["adMare News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/","name":"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/Annonce-1.png","datePublished":"2026-11-17T17:58:01+00:00","dateModified":"2026-11-17T17:58:30+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/Annonce-1.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/Annonce-1.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/admare-portfolio-companies-secure-funding-and-advance-drug-development-as-canadian-life-sciences-investment-hits-five-year-low\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"adMare portfolio companies secure funding and advance drug development as Canadian life sciences investment hits five-year low"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add","name":"Alexis Bouffioux","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/3018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=3018"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/3018\/revisions"}],"predecessor-version":[{"id":3019,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/3018\/revisions\/3019"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/3023"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=3018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=3018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=3018"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=3018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}